Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Landos Biopharma (LABP)
NASDAQ:LABP
Holding LABP?
Track your performance easily
LABP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.50 - $22.94
Previous Close$22.93
Volume50.90K
Average Volume (3M)25.54K
Market Cap
$71.68M
Enterprise Value$29.21M
Total Cash (Recent Filing)$42.47M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.10
Next Earnings
Aug 08, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.99
Shares Outstanding3,125,841
10 Day Avg. Volume15,127
30 Day Avg. Volume25,540
Standard Deviation0.51
R-Squared0.00020
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)1.90
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-8.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.19
Forecast
1Y Price Target
$20.42Price Target Upside-10.95% Downside
Rating ConsensusHold
Number of Analyst Covering2
Landos Biopharma News
PremiumPress Releases
AbbVie Completes Acquisition of Landos Biopharma
PremiumCompany Announcements
Landos Biopharma’s Definitive Merger with AbbVie Subsidiary
Bulls Say, Bears Say
Bulls Say
Financial StrategyThe Landos acquisition represents a cost-effective strategy for AbbVie to expand its portfolio with a novel therapeutic mechanism.
Mergers And AcquisitionsThe favorable deal terms for AbbVie's acquisition of Landos Biopharma signal a strategic move to strengthen their position in the biopharmaceutical industry.
Strategic AcquisitionsAbbVie's acquisition of Landos Biopharma enhances its pipeline with NX-13, a potential game-changer in the treatment of inflammatory bowel diseases.
Bears Say
Acquisition ValuationAcquisition transaction announced—downgrading to Neutral due to a purchase price significantly below the previous price target.
Clinical RisksRisks include clinical setbacks with NX-13, which could adversely affect the company's future prospects.
Operational ChallengesPotential operational challenges due to overlap between the company's and AbbVie's existing commercial/clinical programs.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LABP FAQ
What was Landos Biopharma’s price range in the past 12 months?
Landos Biopharma lowest stock price was $2.50 and its highest was $22.94 in the past 12 months.
What is Landos Biopharma’s market cap?
Currently, no data Available
When is Landos Biopharma’s upcoming earnings report date?
Landos Biopharma’s upcoming earnings report date is Aug 08, 2024 which is 137 days ago.
How were Landos Biopharma’s earnings last quarter?
Landos Biopharma released its earnings results on May 10, 2024. The company reported -$1.433 earnings per share for the quarter, missing the consensus estimate of -$0.88 by -$0.553.
Is Landos Biopharma overvalued?
According to Wall Street analysts Landos Biopharma’s price is currently Overvalued.
Does Landos Biopharma pay dividends?
Landos Biopharma does not currently pay dividends.
What is Landos Biopharma’s EPS estimate?
Landos Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Landos Biopharma have?
Landos Biopharma has 3,126,000 shares outstanding.
What happened to Landos Biopharma’s price movement after its last earnings report?
Landos Biopharma reported an EPS of -$1.433 in its last earnings report, missing expectations of -$0.88. Following the earnings report the stock price went down -0.134%.
Which hedge fund is a major shareholder of Landos Biopharma?
Among the largest hedge funds holding Landos Biopharma’s share is Perceptive Advisors LLC. It holds Landos Biopharma’s shares valued at 32M.
---
Landos Biopharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$20.42 (-10.95% Downside)
$20.42 (-10.95% Downside)
Crowd Wisdom
Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
-70.67%
Trailing 12-Months
Asset Growth
-41.59%
Trailing 12-Months
Company Description
Landos Biopharma
Landos Biopharma Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. The LANCE platform identifies novel therapeutic targets based on predictions of immunometabolic function and creates therapeutic candidates to engage those targets in areas of unmet medical need.
---
LABP Stock 12 Month Forecast
Average Price Target
$20.42
▼(-10.95% Downside)
Technical Analysis
Adverum Biotechnologies
―
Crinetics Pharmaceuticals
―
Denali Therapeutics
―
Bioxcel Therapeutics
―
---